This section shows a summary for the selected study (COSU identifier) or publication (COSP identifier). Studies may have been performed by the Sanger Institute Cancer Genome Project, or imported from the ICGC/TCGA. You can see more information on the help pages.
- Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
- Paper ID
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Cancer medicine, 2020
PMID: 32017404 (view at PubMed or Europe PMC)
- Purpose: Kras mutation and abnormal immune status are associated with pancreatic cancer development and progression. In this study, we evaluated the Kras mutation status in circulating tumor DNA and circulating T cell subsets in a cohort of advanced pancreatic cancer patients.Methods: Samples were retrospectively obtained from a series of 210 pathological advanced pancreatic cancer patients between 2012 and 2014. The Kras mutation status was detected in cell-free circulating tumor DNA (ctDNA) by ddPCR and circulating T cell subsets were analyzed by flow cytometry.Results: Univariate analysis found that tumor node metastasis (TNM) stage, chemotherapy, circulating regulatory T cells, CA19-9 levels, CA125 levels, and Kras<sup>G12D</sup> and Kras<sup>G12V</sup> mutations were significantly related to overall survival in advanced pancreatic cancer patients. Multivariate analysis identified that TNM stage (P = .03, HR:1.422), Tregs (P = .004, HR:1.522), CA19-9 levels (P = .009, HR:1.488), Kras<sup>G12D</sup> mutation (P = .044, HR:1.353), and Kras<sup>G12V</sup> mutation (P = .001, HR:1.667) were independent prognostic markers. Furthermore, we found that Kras<sup>G12V</sup> mutation in ctDNA was correlated with high circulating proportion of Tregs, and patients with both Kras<sup>G12V</sup> mutation and high levels of Tregs were associated with extremely poor survival in advanced pancreatic cancer.Conclusion: Kras<sup>G12V</sup> mutation was associated with high circulating regulatory T cell levels, and both of them predicted worse prognosis in advanced pancreatic cancer patients.
- Paper Status